Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care

Best Practice and Research: Clinical Rheumatology

Volumn 17, Issue 5, 2003, Pages 753-781

  Pincus, Theodore ^a   Sokka, Tuulikki ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Activity; Damage; Measures; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; GOLD SALT; HEMOGLOBIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ARTHRALGIA; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; INFLAMMATION; INJECTION; JOINT INJURY; JOINT PROSTHESIS; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; MEDICAL ASSESSMENT; MONOTHERAPY; MORTALITY; PHYSICIAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; WORK DISABILITY; ARTHROPATHY; DAILY LIFE ACTIVITY; FINANCIAL MANAGEMENT; GASTROINTESTINAL SYMPTOM; HEALTH CARE ORGANIZATION; JOINT CAVITY; KIDNEY FAILURE; METACARPAL BONE; OUTCOMES RESEARCH; PAIN ASSESSMENT; QUANTITATIVE DIAGNOSIS; RADIODIAGNOSIS; TREATMENT OUTCOME;

EID: 0041421004     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6942(03)00077-9     Document Type: Review

References (140)

1. Pincus T & Callahan LF. Prognostic markers of activity and damage in rheumatoid arthritis: Why clinical trials and inception cohort studies indicate more favorable outcomes than studies of patients with established disease. British Journal of Rheumatology 1995; 34: 196-199.
2. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism 1993; 36: 729-740.
3. Tugwell P & Boers M. OMERACT Committee. Proceedings of the OMERACT Conferences on Outcome Measures in Rheumatoid Arthritis Clinical Trials, Maastricht, Netherlands. Journal of Rheumatology 1993; 20: 527-591.
4. Van Riel PLCM. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis (editorial). British Journal of Rheumatology 1993; 31: 793-794.
5. Van Der Heijde DMFM, Van't Hof MA, Van Riel PLCM et al. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Annals of the Rheumatic Diseases 1990; 49: 916-920.
6. Van Der Heijde DMFM, Van't Hof M, Van Riel PLCM & Van De Putte LBA. Development of a disease activity score based on judgment in clinical practice by rheumatologists. Journal of Rheumatology 1993; 20: 579-581.
7. Scott DL, Grindulis KA, Struthers GR et al. Progression of radiological changes in rheumatoid arthritis. Annals of the Rheumatic Diseases 1984; 43: 8-17.
8. Pincus T, Callahan LF, Sale WG et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis and Rheumatism 1984; 27: 864-872.
9. Hawley DJ & Wolfe F. Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: Results of short term clinical trials and observational studies versus long term observational studies. Arthritis Care Research 1992; 5: 130-136.
10. Sharp JT, Wolfe F, Mitchell DM & Bloch DA. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis and Rheumatism 1991; 34: 660-668.
11. Egsmose C, Lund B, Borg G et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. Journal of Rheumatology 1995; 22: 2208-2213.
12. Fex E, Jonsson K, Johnson U & Eberhardt K. Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. British Journal of Rheumatology 1996; 35: 1106-1115.
13. Mulherin D, Fitzgerald O & Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that pathogenesis of synovial inflammation and articular erosion may differ. British Journal of Rheumatology 1996; 35: 1263-1268.
14. Callahan LF, Pincus T, Huston III JW et al. Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. Arthritis Care Research 1997; 10: 381-394.
15. Leirisalo-Repo M, Paimela L, Peltomaa R et al. Functional and radiological outcome in patients with early RA - A longitudinal observational study. Arthritis and Rheumatism 1999; 42: S130.
16. Graudal N, Tarp U, Jurik AG et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: Longterm course and association to radiographic progression. Journal of Rheumatology 2000; 27; 47-57.
17. Welsing PMJ, Van Gestel AM, Swinkels HL et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis and Rheumatism 2001; 44: 2009-2017.
18. Pincus T & Sokka T. Partial control of Core Data Set measures and Disease Activity Score (DAS) measures of inflammation does not prevent long-term damage: Evidence from longitudinal observations over 5-20 years. Clinical and Experimental Rheumatology 2002; 20(supplement 27): S42-S48.
19. American Rheumatism Association, Dictionary of the Rheumatic Diseases. Signs and Symptoms, vol. 1. New York: Contact Associates International, 1982.
20. Fuchs HA, Callahan LF, Kaye JJ et al. Radiographic and joint count findings of the hand in rheumatoid arthritis: Related and unrelated findings. Arthritis and Rheumatism 1988; 31: 44-51.
21. Ritchie DM, Boyle JA, McInnes JM et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Quarterly Journal of Medicine, New Series 1968; 37: 393-406.
22. Egger MJ, Huth DA, Ward JR et al. Reduced joint count indices in the evaluation of rheumatoid arthritis. Arthritis and Rheumatism 1985; 28: 613-619.
23. Fuchs HA, Brooks RH, Callahan LF & Pincus T. A simplified twenty-eight joint quantitative articular index in rheumatoid arthritis. Arthritis and Rheumatism 1989; 32: 531-537.
24. Sokka T & Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis and Rheumatism 2003; 48: 313-318.
25. Pincus T, Brooks RH & Callahan LF. A proposed standard protocol to evaluate rheumatoid arthritis (SPERA) that includes measures of inflammatory activity, joint damage, and longterm outcomes. Journal of Rheumatology 1999; 26: 473-480.
26. Kraan MC, Versendaal H, Jonker M et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis and Rheumatism 1998; 41: 1481-1488.
27. Soden M, Rooney M, Cullen A et al. Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis. British Journal of Rheumatology 1989; 28: 287-292.
28. De Bois MHW, Tak PP, Arndt JW et al. Joint scintigraphy for quantification of synovitis with 99mTc-labelled human immunoglobulin G compared to histological examination. Clinical and Experimental Rheumatology 1995; 13: 155-159.
29. Steinbrocker O, Traeger CH & Batterman RC. Therapeutic criteria in rheumatoid arthritis. Journal of the American Medical Association 1949; 140: 659-662.
30. Sharp JT, Lidsky MD, Collins LC & Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism 1971; 14: 706-720.
31. Sharp JT, Lidsky MD & Duffy J. Clinical responses during gold therapy for rheumatoid arthritis: Changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities. Arthritis and Rheumatism 1982; 25: 540-549.
32. Sharp JT. Radiographic evaluation of the course of articular disease. Clinical Rheumatic Disease 1983; 9: 541-557.
33. Larsen A. A radiological method for grading the severity of rheumatoid arthritis. Academic Dissertation, University of Helsinki, 1974.
34. Larsen A, Dale K & Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologica (Diagn) (Stockholm) 1977; 18: 481-491.
35. Nance Jr. EP, Kaye JJ, Callahan LF et al. Observer variation in quantitative assessment of rheumatoid arthritis: Part I. Scoring erosions and joint space narrowing. Investigative Radiology 1986; 21: 922-927.
36. Kaye JJ, Nance EP, Callahan LF et al. Observer variation in quantitative assessment of rheumatoid arthritis: Part II. A simplified scoring system. Investigative Radiology 1987; 22: 41-46.
37. Kaye JJ, Callahan LF, Nance Jr. EP et al. Bony ankylosis in rheumatoid arthritis: Associations with longer duration and greater severity of disease. Investigative Radiology 1987; 22: 303-309.
38. Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. American Journal of Medicine 1987; 75(supplement 6A): 35-47.
39. Van Der Heijde DMFM, Van Leeuwen MA, Van Riel PLCM et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis and Rheumatism 1992; 35: 26-34.
40. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in longterm studies? Journal of Rheumatology 1995; 22: 1974-1975.
41. Kaarela K & Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. Journal of Rheumatology 1997; 24: 1285-1287.
42. Rau R & Herborn G. A modified version of Larsen's scoring method to assess radiologic changes in rheumatoid arthritis. Journal of Rheumatology 1995; 22: 1976-1982.
43. Rau R, Wassenberg S, Herborn G et al. Identification of radiologic healing phenomena in patients with rheumatoid arthritis. Journal of Rheumatology 2001; 28: 2608-2615.
44. Pincus T, Callahan LF, Brooks RH et al. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Annals of Internal Medicine 1989; 110: 259-266.
45. Sokka T, Kankainen A & Hannonen P. Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. Arthritis and Rheumatism 2000; 43: 386-389.
46. Wolfe F & Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. Journal of Rheumatology 1994; 21: 1227-1237.
47. Wolfe F & Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. Journal of Rheumatology 2001; 28: 1817-1824.
48. Sokka T & Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. Journal of Rheumatology 2003; 30: 1138-1146.
49. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathologica et Microbiologica Scandinavica 1940; 17: 172-178.
50. Rose HM, Ragan C, Pearce E & Lipman MO. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proceedings of the Society of Experimental Biology and Medicine 1948; 68: 1-6.
51. Aho K, Heliövaara M, Maatela J et al. Rheumatoid factors antedating clinical rheumatoid arthritis. Journal of Rheumatology 1991; 18: 1282-1284.
52. Jacoby RK, Jayson MIV & Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: A clinical study of 100 patients with 11-year follow-up. British Medical Journal 1973; 2: 96-100.
53. Wolfe F & Pincus T. Listening to the patient: A practical guide to self-report questionnaires in clinical care. Arthritis and Rheumatism 1999; 42: 1797-1808.
54. Pincus T & Wolfe F. An infrastructure of patient questionnaires at each rheumatology visit: Improving efficiency and documenting care. Journal of Rheumatology 2000; 27: 2727-2730.
55. Katz S, Ford AB, Moskowitz RW et al. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. Journal of the American Medical Association 1963; 185: 914-919.
56. Fries JF, Spitz P, Kraines RG & Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatism 1980; 23: 137-145.
57. Pincus T, Summey JA, Soraci Jr. SA et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis and Rheumatism 1983; 26: 1346-1353.
58. Wolfe F. A brief health status instrument: CLINHAQ. Arthritis and Rheumatism 1989; 32: S99.
59. Pincus T, Swearingen C & Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis and Rheumatism 1999; 42: 2220-2230.
60. Meenan RF, Gertman PM & Mason JH. Measuring health status in arthritis: The arthritis impact measurement scales. Arthritis and Rheumatism 1980; 23: 146-152.
61. Bellamy N, Buchanan WW, Goldsmith CH et al. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. Journal of Rheumatology 1988; 15: 1833-1840.
62. Bellamy N. Pain assessment in osteoarthritis: Experience with the WOMAC osteoarthritis index. Seminars in Arthritis and Rheumatism 1989; 18(supplement 2): 14-17.
63. Ware Jr. JE & Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care 1992; 30: 473-481.
64. Melzack R. The McGill Pain Questionnaire: Major properties and scoring methods. Pain 1975; 1: 277-299.
65. Melzack R. The McGill Pain Questionnaire. In Melzack R (ed.) Pain Measurement and Assessment New York: Raven Press, 1983, pp 41-47.
66. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30: 191-197.
67. Huskisson EC. Measurement of pain. The Lancet 1974; ii: 1127-1131.
68. Huskisson EC. Assessment for clinical trials. Clinical Rheumatic Disease 1976; 2: 37-49.
69. Scott J & Huskisson EC. Graphic representation of pain. Pain 1976; 2: 175-184.
70. Scott J & Huskisson EC. Vertical or horizontal visual analogue scales. Annals of the Rheumatic Diseases 1979; 38: 560.
71. Huskisson EC. Measurement of pain. Journal of Rheumatology 1982; 9: 768-769.
72. Huskisson EC. Visual analogue scales. In Melzack R (ed.) Pain Measurement and Assessment. New York: Raven Press, 1983, pp 33-37.
73. Lee P, Baxter A, Dick WC & Webb J. An assessment of grip strength measurement in rheumatoid arthritis. Scandinavian Journal of Rheumatology 1974; 3: 17-23.
74. Deodhar SD, Dick WC, Hodgkinson R & Buchanan WW. Measurement of clinical response to anti-inflammatory drug therapy in rheumatoid arthritis. Quarterly Journal of Medicine 1973; 42: 387-401.
75. Clawson DK, Souter WA, Carthum CJ & Hymen ML. Functional assessment of the rheumatoid hand. Clinical Orthopedics 1971; 77: 203-210.
76. Pincus T & Callahan LF. Rheumatology function tests: Grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis. Journal of Rheumatology 1992; 19: 1051-1057.
77. Pincus T, Callahan LF & Vaughn WK. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. Journal of Rheumatology 1987; 14: 240-251.
78. Pincus T, Brooks RH & Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Annals of Internal Medicine 1994; 120: 26-34.
79. Callahan LF, Bloch DA & Pincus T. Identification of work disability in rheumatoid arthritis: Physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variables. Journal of Clinical Epidemiology 1992; 45: 127-138.
80. Wolfe F, Pincus T, Thompson AK & Doyle J. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Care Research 2003; 49: 59-63.
81. Steinbrocker O & Blazer A. A therapeutic score card for rheumatoid arthritis. New England Journal of Medicine 1946; 14: 501-506.
82. Lansbury J. A method for summation of the systemic indices of rheumatoid activity. American Journal of Medical Science 1956; 232: 300-310.
83. Paulus HE, Egger MJ, Ward JR, Williams HJ & Cooperative Systemic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis and Rheumatism 1990; 33: 477-484.
84. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995; 38: 727-735.
85. Felson DT, Anderson JI, Lange MLM et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis and Rheumatism 1998; 41: 1564-1570.
86. Pincus T, Strand V, Koch G et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis and Rheumatism 2003; 48: 625-630.
87. Strand V, Tugwell P, Bombardier C et al. Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis and Rheumatism 1999; 42: 1870-1878.
88. Tugwell P, Wells G, Strand V et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide rheumatoid arthritis investigators group. Arthritis and Rheumatism 2000; 43: 506-514.
89. Sackett DL. The competing objectives of randomized trials. New England Journal of Medicine 2000; 303: 1059-1060.
90. Freiman JA, Chalmers TC, Smith H Jr. & Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: Survey of 71 'negative' trials. New England Journal of Medicine 1978; 299: 690-694.
91. Sackett DL & Gent M. Controversy in counting and attributing events in clinical trials. New England Journal of Medicine 1979; 301: 1410-1412.
92. Huskisson EC. Important factors in the success and failure of clinical trials (closing remarks). Agents and Actions 1980; 7(supplement): 323-324.
93. Freireich EJ. The randomized clinical trial as an obstacle to clinical research. In Varco RL & Delaney JP (eds) Controversy in Surgery. Philadelphia: W.B. Saunders, 1983, pp 5-12.
94. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Annals of Internal Medicine 1983; 99: 544-550.
95. Diamond GA & Forrester JS. Clinical trials and statistical verdicts: Probable grounds for appeal. Annals of Internal Medicine 1983; 98: 385-394.
96. Chalmers TC, Celano P, Sacks HS & Smith Jr. H. Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine 1983; 309: 1358-1361.
97. Bombardier C & Tugwell P. Controversies in the analysis of longterm clinical trials of slow acting drugs (editorial). Journal of Rheumatology 1983; 12: 403-405.
98. Guyatt G, Sackett D, Taylor DW et al. Determining optimal therapy - Randomized trials in individual patients. New England Journal of Medicine 1986; 314: 889-892.
99. Hawley DJ & Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: Analysis of 122 studies. Journal of Rheumatology 1991; 18: 1008-1014.
100. Felson DT, Anderson JJ & Meenan RF. Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis and Rheumatology 1990; 33: 140-149.
101. Gotzche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Controlled Clinical Trials 1989; 10: 31-56.
102. Klippel JH. Comment: Winning the battle, losing the war? Another editorial about RA. Journal of Rheumatology 1990; 17: 1118-1122.
103. Sanz I, Dang H, Takei M et al. VH sequence of a human anti-SM autoantibody. Evidence that autoantibodies can be un-mutated copies of germline genes. Journal of Immunology 1989; 142: 883-887.
104. Concato J, Shah N & Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine 2000; 342: 1887-1892.
105. Horwitz RI. Clinical versus statistical considerations in the design and analysis of clinical research. Journal of Clinical Epidemiology 1998; 51: 305-307.
106. Feinstein AR & Horwitz RI. Problems in the 'evidence' of 'evidence-based medicine'. American Journal of Medicine 1997; 103: 529-535.
107. Pincus T. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials. Journal of Clinical Epidemiology 1988; 41: 1037-1041.
108. Pincus T & Wolfe F. Response to letter: Gold therapy for rheumatoid arthritis: Challenges to traditional paradigms. Annals of Internal Medicine 1992; 117: 169-170.
109. Pincus T. Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Seminars in Arthritis and Rheumatism 1993; 23(supplement 1): 2-10.
110. Pincus T & Stein M. What is the best source of useful data on the treatment of rheumatoid arthritis: Clinical trials, clinical observations, or clinical protocols? Journal of Rheumatology 1995; 22: 1611-1617.
111. Rothwell PM. Can overall results of clinical trials be applied to all patients? The Lancet 1995; 345: 1616-1619.
112. Pincus T. Analyzing long-term outcomes of clinical care without randomized controlled clinical trials: The consecutive patient questionnaire database. Advances: The Journal of Mind-Body Health 1997; 13: 3-32.
113. Pincus T & Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clinical and Experimental Rheumatology 1997; 15(supplement 17): S27-S38.
114. Felson DT, Anderson JJ & Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: Results of two metaanalyses. Arthritis and Rheumatism 1990; 33: 1449-1461.
115. Pincus T, Marcum SB & Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. Journal of Rheumatology 1992; 19: 1885-1894.
116. Krause D, Schleusser B, Herborn G & Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis and Rheumatism 2000; 43: 14-21.
117. Choi HK, Hernán MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. The Lancet 2002; 359: 1173-1177.
118. St. Clair EW, Wagner CL, Fasanmade AA et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2002; 46: 1451-1459.
119. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis and Rheumatism 2002; 46: 1443-1450.
120. Fleming TR & DeMets DL. Surrogate end points in clinical trials: Are we being misled? Annals of Internal Medicine 1996; 125: 605-613.
121. Pincus T. Assessment of long-term outcomes of rheumatoid arthritis. Rheumatic Disease Clinics of North America 1995; 21: 619-654.
122. Medsger Jr TA, Robinson H & Masi AT. Factors affecting survivorship in polymyositis: A life-table study of 124 patients. Arthritis and Rheumatism 1971; 14: 249-258.
123. Daniels M & Hill AB. Chemotherapy of pulmonary tuberculosis in young adults: An analysis of the combined results of three medical research council trials. British Medical Journal 1952; 1: 1162-1168.
124. Pincus T, Gibofsky A & Weinblatt ME. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: Better treatments but a shortage of rheumatologists. Arthritis and Rheumatism 2002; 46: 851-854
125. Neaton JD & Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Archives of Internal Medicine 1992; 152: 56-64.
126. Stein CM, Wood AJJ & Pincus T. Implementation of multiple outpatient formularies: Undesirable effects. Clinical Pharmacology and Therapeutics 1997; 61: 1-7.
127. Ader R. The placebo effect as a conditioned response. In Ader R, Weiner H & Baum A (eds) Experimental Foundations of Behavioral Medicine: Conditioning Approaches. Hillsdale, NJ: Erlbaum, 1988, pp 47-66.
128. Spiro HM. Doctors, Patients, and Placebos. New Haven: Yale University Press, 1986.
129. Chalmers TC, Block JB & Lee S. Controlled studies in clinical cancer research. New England Journal of Medicine 1972; 287: 75-78.
130. Stein CM & Pincus T. Placebo-controlled studies in rheumatoid arthritis: Ethical issues. The Lancet 1999; 353: 400-403.
131. Yelin E, Meenan R, Nevitt M & Epstein W. Work disability in rheumatoid arthritis: Effects of disease, social, and work factors. Annals of Internal Medicine 1980; 93: 551-556.
132. Fries JF, Williams CA, Bloch DA & Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models. American Journal of Medicine 1991; 91: 213-222.
133. Griffin MR, Ray WA & Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Annals of Internal Medicine 1988; 109: 359-363.
134. Wolfe F & Pincus T. Standard self-report questionnaires in routine clinical and research practice - An opportunity for patients and rheumatologists. Journal of Rheumatology 1991; 18: 643-646.
135. Wolfe F & Pincus T. Data collection in the clinic. Rheumatic Disease Clinics of North America 1991; 21: 321-358.
136. Callahan LF, Smith WJ & Pincus T. Self-report questionnaires in five rheumatic diseases: Comparisons of health status constructs and associations with formal education level. Arthritis Care Research 1989; 2: 122-131.
137. Tugwell P, Bombardier C, Buchanan WW et al. The MACTAR patient preference disability questionnaire - An individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. Journal of Rheumatology 1987; 14: 446-451.
138. Wolfe F. Data collection and utilization: A methodology for clinical practice and clinical research. In Wolfe F & Pincus T (eds) Rheumatoid Arthritis: Pathogenesis, Assessment, Outcome, and Treatment. New York Marcel Dekker Inc, 1994, pp 463-514.
139. Lindblad S & Hedfors E. Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis. Arthritis and Rheumatism 1987; 30: 1081-1088.
140. Pincus T & Callahan LF. The side effects of rheumatoid arthritis: Joint destruction, disability and early mortality. British Journal of Rheumatology 1993; 32(supplement 1): 28-37.